Clinical Trial Update: Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients [Phase 2]

View source ↗

Summary

Phase II study assessing the efficacy and safety of TLC388 in patients with neuroendocrine carcinomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• TLC388

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Neuroendocrine Carcinomas | Phase 2 | Status: COMPLETED